User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse




Journal Article

Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma


Ullrich,  A.
Ullrich, Axel / Molecular Biology, Max Planck Institute of Biochemistry, Max Planck Society;

There are no locators available
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available

Zeng, J. Z., Wang, H. Y., Chen, Z. J., Ullrich, A., & Wu, M. C. (2002). Molecular cloning and characterization of a novel gene which is highly expressed in hepatocellular carcinoma. Oncogene, 21(32), 4932-4943.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0010-6EAE-A
To gain new insight into the molecular mechanism underlying the pathogenesis of human primary hepatocellular carcinoma (HCC), we searched for HCC-specific molecules through screening genes that are differentially expressed between cancerous and noncancerous counterparts of liver and identified a novel HCC- associated gene, HCCA1 encoding a similar to80 kDa cytoplasmic protein that contains several proline-rich motifs likely for SH3-binding. HCCA1 transcript, albeit present in some adult tissues, is up-regulated selectively in HCC but not in other tumor cells. High expression of HCCA1 occurs as a late event frequently (89.2%) in HCCs and correlated significantly with the degree of tumor progression. When treated with antisense oligonucleotides to HCCA1, HCCA1 expression in HCC cells (HuH- 7) was effectively suppressed and cell growth was down- regulated in a time- and dose-dependent manner. Furthermore, HuH-7 cells harboring the HCCA1 antisense expression clone displayed a remarkably reduced efficiency in colony formation. Together, these data strongly suggest that HCCA1 is a positive effector in cell proliferation and contributes to HCC carcinogenesis and progression. We believe that this protein will serve as a novel useful marker for HCC and is a potential target for pharmaceutical intervention of this malignant disease.